Dianthus Therapeutics Inc.

The chronic inflammatory demyelinating polyneuropathy treatment market is projected to grow positively by 2036 across leading markets, driven by an expanding diagnosed patient population, improved disease awareness, and the anticipated introduction of novel mechanism-based therapies. The United States accounted for the largest market size in 2025 compared with the EU4 countries, the United Kingdom, and Japan. Key companies advancing new treatments include Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, and Takeda, with promising pipeline therapies such as Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, and TAK-411. The prevalence of CIDP is estimated at around 5 to 7 cases per 100,000 individuals in the UK, and the market is seeing increased demand for targeted and long-acting therapies including subcutaneous immunoglobulin formulations and FcRn inhibitors.

Dianthus Therapeutics shares have surged 88.9% over the past six months, driven by growing investor confidence in its lead asset claseprubart and a strong financial position. The company plans to initiate a pivotal phase III EMERGE study for generalized myasthenia gravis in 2026, with top-line data expected in the second half of 2028, and claseprubart recently achieved an early GO decision in the phase III CAPTIVATE study for chronic inflammatory demyelinating polyneuropathy. A phase II MoMeNtum study in multifocal motor neuropathy remains on track for top-line results in the fourth quarter of 2026. Dianthus also advanced its second candidate, DNTH212, into a phase I study in December 2025, with initial data expected in the second half of 2026. The company raised approximately $719 million in gross proceeds in March and held about $1.2 billion in cash, equivalents, and investments as of March 31, 2026, expected to fund operations into 2030.